Health Equity: Design culturally tailored interventions

AD-Related Dementias Focus

Implement culturally tailored multimodal intervention trials and drug therapy trials to reduce AD/ADRD burden in populations facing disparities.

2027 NOT-NS-21-047: Administrative Supplements to Promote Diversity for NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees RFA-NS-23-001: Pragmatic Clinical Trials in Community Settings to Decrease or Prevent VCID Outcomes, Including in Populations that Experience Health Disparities (U01 Clinical Trial Required) PAR-24-270: ADRD Risk and Disease Following Nervous System Exposures at Biological Interfaces with the Environment (R01 - Clinical Trial Not Allowed) 10.H Achieved Implement culturally tailored multimodal intervention trials and drug therapy trials reduce AD/ADRD burden DN 2019 ADRD Summit: Health Disparities in AD/ADRD, Focus Area 2: Resolve AD/ADRD Health Disparities by Discovering Culturally Appropriate Pathways to Effective Prevention and Treatments, Milestone 4 Workshop: Health Disparities and Inequities in Neurological Disorders Trial Design Select projects funded in FY21 2020

  • Initiate one new clinical trial targeting AD/ADRD specifically in a population that experiences health disparities in dementia.

Summary of Key Accomplishments

The ongoing NINDS-funded ARCADIA CSI study is a multicenter, biomarker-driven, randomized phase 3 clinical trial of apixaban, a type of blood thinner, versus aspirin in individuals who have had a recent stroke of unknown cause. More than 1,000 individuals are being recruited over 2.5 years at 120 sites in the NIH StrokeNet clinical trial network. Participants, including those from NIH defined health disparities populations, will be followed for 1.5-7 years to understand the effects of apixaban on recurrent stroke as well as dementia-related outcomes and determine its safety with respect to hemorrhaging in the brain. Dementia-related neuroimaging and key measures of cognitive decline were recently added to the ancillary study using AD/ADRD funds.

The key accomplishments summary is current as of July 2022.